This article has been updated with a statement from Glaxo Smith Kline.
A federal judge in Delaware has awarded British inhaler company Vectura an additional $10.5 million in compensatory damages from Glaxo Smith Kline (NYSE:GSK) in a patent dispute.
In May, a jury awarded Vectura $89.7 million in damages for the period from August 2016 through December 2018 for an infringement on Vectura’s U.S. patent 8303991 by sales of three of GlaxoSmithKline’s Ellipta products. The jury based the $89.7 million on ongoing royalties of 3% on U.S. sales of those products.
Get the full story on our sister site, Drug Delivery Business News.